{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-26-000023","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.267081+00:00","generated_at":"2026-05-14T23:34:30.676469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance","bullets":["GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.","Point of Care revenue $113M (-34% YoY) on weak respiratory season; Labs $353M (-5%); Immunohematology $138M (+8%).","Full-year 2026 guidance cut: revenue $2.70-2.75B (prev. $2.7-2.9B), adj. EBITDA $615-630M (prev. $630-670M), adj. EPS $1.80-2.00 (prev. $2.00-2.42).","Acquired LEX Diagnostics in April for ultra-fast point-of-care molecular diagnostics platform.","U.S. launch of High-Sensitivity Troponin and international rollout of VITROS 450 platform underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-26-000023","json":"https://secwatch.observer/filing/0001906324-26-000023.json","markdown":"https://secwatch.observer/filing/0001906324-26-000023.md","text":"https://secwatch.observer/filing/0001906324-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/0001906324-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/qdel-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:34:30.676469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9579af1aac630a38998a15c2f18b482d689ecd85","claim":"QuidelOrtho Corp reported first quarter ended March 29, 2026 results: revenue $620 million. Guidance lowered.","evidence_excerpt":"Key First Quarter 2026 Results: (all comparisons are to the prior year period) • Total revenu e was $620 million , as reported ◦ Point of Care revenue of $113 million declined by 34% as reported and 35% in constant currency, primarily due to a significantly weaker respiratory season compared to the first quarter of 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632426000023/0001906324-26-000023-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 29, 2026"},{"label":"Revenue","value":"$620 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}